🟢 Summit Therapeutics is trading 4.48% up today with no clear catalyst

Summit Therapeutics is trading at $14.59 (+4.48%) with no clear catalyst identified.

• No new company announcement, clinical update, financing, or regulatory catalyst was identified for August 10, 2026.
• Summit’s latest release, dated August 5, announced the Phase II/III HARMONi-GU1 bladder-cancer study but did not link it to share-price movement.
• The broader market is slightly weaker; recent coverage remains focused on ivonescimab and its expected November 14 FDA decision.